NHL: Diffuse Large B Cell Lymphoma Forecast and Market Analysis to 2034

  • ID: 3797452
  • Drug Pipelines
  • 162 pages
  • Datamonitor Healthcare
1 of 3
Diffuse large B-cell lymphoma (DLBCL) is a form of hematological malignancy that affects B lymphocytes. This cancer is the most common type of non-Hodgkin’s lymphoma (NHL), accounting for about one-third of all newly diagnosed cases. The disease occurs predominantly in older people, with a median age of diagnosis around 65 years, and has a slightly higher prevalence in men than in women. DLBCL is categorized as an aggressive form of NHL; after initial onset the cancer advances quickly and can be fatal if left untreated. However, prompt and suitable treatment can lead to cure in more than 50% of cases.

Recent events and opinion
  • Market growth will be driven by increasing disease prevalence and the approval of pipeline therapies targeted at patient populations with unmet needs.
  • R-CHOP chemotherapy remains the standard of care first-line treatment for DLBCL.
  • Incident cases of the three major subtypes of NHL will increase by at least a quarter over the forecast period.
  • Rituxan remains the standard of care in the treatment of DLBCL and is likely to face biosimilar erosion upon patent expiry.
  • The DLBCL late-stage pipeline has shrunk dramatically after the suspension of three Phase III trials.
Note: Product cover images may vary from those shown
2 of 3
Table of Contents (Forecast, Treatment, Epidemiology Datapacks included)
FORECAST: DIFFUSE LARGE B-CELL LYMPHOMA (Published on 16 August 2016)
OVERVIEW
EXECUTIVE SUMMARY
MARKET OVERVIEW AND TRENDS
MARKET DEFINITION AND METHODOLOGY
BIOSIMILAR RITUXIMAB
IMBRUVICA (IBRUTINIB)
REVLIMID (LENALIDOMIDE)
RITUXAN (RITUXIMAB)
PRIMARY RESEARCH METHODOLOGY

TREATMENT: DIFFUSE LARGE B-CELL LYMPHOMA (Published on 26 May 2016)
OVERVIEW
EXECUTIVE SUMMARY
PRIMARY RESEARCH METHODOLOGY
DISEASE DEFINITION AND DIAGNOSIS
PATIENT SEGMENTATION
COUNTRY TREATMENT TREES
CURRENT TREATMENT OPTIONS
PRESCRIBING TRENDS

EPIDEMIOLOGY: DIFFUSE LARGE B-CELL LYMPHOMA (Published on 11 April 2018)
OVERVIEW
DISEASE BACKGROUND
METHODOLOGY
FORECAST
BIBLIOGRAPHY
APPENDIX: ADDITIONAL SOURCES

MARKETED DRUGS: DIFFUSE LARGE B-CELL LYMPHOMA (Published on 16 August 2016)
OVERVIEW
EXECUTIVE SUMMARY
PRODUCT OVERVIEW
PRODUCT PROFILE: RITUXAN
PIPELINE: DIFFUSE LARGE B-CELL LYMPHOMA (Published on 16 August 2016)
OVERVIEW
EXECUTIVE SUMMARY
CLINICAL PIPELINE OVERVIEW
TARGET PRODUCT PROFILE
RECENTLY DISCONTINUED DRUGS
PRODUCT PROFILE (LATE STAGE): IMBRUVICA
PRODUCT PROFILE (LATE STAGE): KEYTRUDA
PRODUCT PROFILE (LATE STAGE): REVLIMID

List of Figures
Figure 1: Diffuse large B-cell lymphoma market value across the US, Japan, and five major EU markets, by country, 2016-25
Figure 2: Diffuse large B-cell lymphoma sales in the US, by marketing status, 2016-25
Figure 3: Diffuse large B-cell lymphoma sales in Japan, by marketing status, 2016-25
Figure 4: Diffuse large B-cell lymphoma sales in the five major EU markets, by marketing status, 2016-25
Figure 5: Methodology flow for the author's diffuse large B-cell lymphoma forecast
Figure 6: Price sources and calculations, by country
Figure 7: Biosimilar rituximab sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country, 2016-25
Figure 8: Imbruvica sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country, 2016-25
Figure 9: Revlimid sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country, 2016-25
Figure 10: Rituxan sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country, 2016-25
Figure 11: Proportion of DLBCL patients diagnosed at each stage of disease, by country (%)
Figure 12: Top three first-line induction therapy regimens prescribed for the treatment of Stage I-II DLBCL, by country
Figure 13: Top three first-line induction therapy regimens prescribed for the treatment of Stage III-IV DLBCL, by country
Figure 14: Top three consolidation therapies prescribed for the treatment of Stage I-II DLBCL, by country
Figure 15: Top three consolidation therapies prescribed for the treatment of Stage III-IV DLBCL, by country
Figure 16: Top three second-line therapy regimens prescribed for the treatment of Stage I-IV stem cell eligible DLBCL patients, by country
Figure 17: Top three second-line therapy regimens prescribed for the treatment of Stage I-IV DLBCL patients not eligible for stem cell transplantation, by country
Figure 18: Top three third-line therapy regimens prescribed to Stage I-IV DLBCL patients who have previously received a stem cell transplant, by country
Figure 19: Top three third line therapy regimens prescribed to Stage I-IV DLBCL patients who have not previously received a stem cell transplant, by country
Figure 20: Trends in incident cases of NHL in the US, Japan, and five major EU markets, 2017-37
Figure 21: Trends in incident cases of DLBCL in the US, Japan, and five major EU markets, 2017-37
Figure 22: Trends in incident cases of FL in the US, Japan, and five major EU markets, 2017-37
Figure 23: Trends in incident cases of MCL in the US, Japan, and five major EU markets, 2017-37
Figure 24: Drug assessment summary of key marketed and pipeline drugs for diffuse large B-cell lymphoma
Figure 25: Rituxan for diffuse large B-cell lymphoma - SWOT analysis
Figure 26: Drug assessment summary for Rituxan in diffuse large B-cell lymphoma
Figure 27: Drug assessment summary for Rituxan in diffuse large B-cell lymphoma
Figure 28: Phase Ib results for Imbruvica in patients with CD20-positive B-cell non-Hodgkin’s lymphoma
Figure 29: Imbruvica for diffuse large B-cell lymphoma - SWOT analysis
Figure 30: Drug assessment summary for Imbruvica in diffuse large B-cell lymphoma
Figure 31: Drug assessment summary for Imbruvica in diffuse large B-cell lymphoma
Figure 32: Keytruda for diffuse large B-cell lymphoma - SWOT analysis
Figure 33: Drug assessment summary for Keytruda in diffuse large B-cell lymphoma
Figure 34: Drug assessment summary for Keytruda in diffuse large B-cell lymphoma
Figure 35: Revlimid for diffuse large B-cell lymphoma - SWOT analysis
Figure 36: Drug assessment summary for Revlimid in diffuse large B-cell lymphoma
Figure 37: Drug assessment summary for Revlimid in diffuse large B-cell lymphoma

List of Tables
Table 1: Diffuse large B-cell lymphoma market value across the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 2: Diffuse large B-cell lymphoma sales in the US, by brand and marketing status ($m), 2016-25
Table 3: Diffuse large B-cell lymphoma sales in Japan, by brand and marketing status ($m), 2016-25
Table 4: Diffuse large B-cell lymphoma sales in the five major EU markets, by brand and marketing status ($m), 2016-25
Table 5: Summary of drug classes and molecules included in the diffuse large B-cell lymphoma patient-based forecast
Table 6: Exchange rates used for calculating prices
Table 7: Patent expiry dates for key marketed brands in diffuse large B-cell lymphoma in the US, Japan, and five major EU markets, by region, 2016-25
Table 8: Forecast launch dates of key late-stage pipeline products in diffuse large B-cell lymphoma in the US, Japan, and five major EU markets, by region, 2016-25
Table 9: Pricing assumptions for biosimilar rituximab
Table 10: Biosimilar rituximab sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 11: Biosimilar rituximab patient numbers for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country, 2016-25
Table 12: Imbruvica sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 13: Imbruvica patient numbers for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country, 2016-25
Table 14: Revlimid sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 15: Revlimid patient numbers for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country, 2016-25
Table 16: Rituxan sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 17: Rituxan patient numbers for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country, 2016-25
Table 18: Medical hematologists and hemato-oncologists surveyed for the diffuse large B-cell lymphoma primary research study, 2016
Table 19: Medical hematologists and hemato-oncologists surveyed for the DLBCL primary research study, 2016
Table 20: Non-Hodgkin’s lymphoma five-year survival rates, by stage of diagnosis, 2005-11
Table 21: Immunophenotypic diagnosis of DLBCL
Table 22: International prognostic Index for DLBCL
Table 23: Risk groups in DLBCL classified by the international prognostic index
Table 24: Ann Arbor staging used in lymphoma
Table 25: Targeted drugs for the treatment of DLBCL
Table 26: Main chemotherapies for the treatment of DLBCL
Table 27: Cancer registry databases used as a source of NHL, DLBCL, FL, and MCL incidence data, by country
Table 28: Ann Arbor classification system
Table 29: Incident cases of NHL in the US, Japan, and five major EU markets, 2017-37
Table 30: Incident cases of DLBCL in the US, Japan, and five major EU markets, 2017-37
Table 31: Incident cases of FL in the US, Japan, and five major EU markets, 2017-37
Table 32: Incident cases of MCL in the US, Japan, and five major EU markets, 2017-37
Table 33: Key marketed drugs for diffuse large B-cell lymphoma
Table 34: Rituxan drug profile
Table 35: Rituxan pivotal trial data in diffuse large B-cell lymphoma
Table 36: Rituxan Phase III data in diffuse large B-cell lymphoma
Table 37: Phase III pipeline products in development for diffuse large B-cell lymphoma
Table 38: Rituxan drug profile
Table 39: Rituxan pivotal trial data in diffuse large B-cell lymphoma
Table 40: Late-stage compounds that were recently discontinued for diffuse large B-cell lymphoma
Table 41: Imbruvica drug profile
Table 42: Imbruvica Phase III trial in diffuse large B-cell lymphoma
Table 43: Keytruda drug profile
Table 44: Revlimid drug profile
Table 45: Revlimid Phase III trials in diffuse large B-cell lymphoma
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll